1. Benign and Intermediate-grade Melanocytic Tumors With BRAF Mutations and Spitzoid Morphology: A Subset of Melanocytic Neoplasms Distinct From Melanoma
- Author
-
Shantel Olivares, Sarah Benton, Jeffrey Zhao, Sepideh Asadbeigi, Klaus J. Busam, Bin Zhang, and Pedram Gerami
- Subjects
Proto-Oncogene Proteins B-raf ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,medicine.disease_cause ,Pathology and Forensic Medicine ,Nevus, Epithelioid and Spindle Cell ,Medicine ,Humans ,HRAS ,Intermediate Grade ,skin and connective tissue diseases ,neoplasms ,Melanoma ,Nevus ,In Situ Hybridization, Fluorescence ,Mutation ,integumentary system ,medicine.diagnostic_test ,business.industry ,Syndrome ,medicine.disease ,Cutaneous melanoma ,Kamino bodies ,Immunohistochemistry ,Surgery ,Anatomy ,business ,Fluorescence in situ hybridization - Abstract
The current classification of Spitz neoplasms in the World Health Organization (WHO), Fourth Edition defines Spitz neoplasms as melanocytic proliferations with characteristic Spitz morphology and a Spitz-associated genomic fusion or HRAS mutation. In contrast, melanocytic neoplasms with BRAF mutations are considered typical of common acquired nevi, dysplastic nevi, and melanomas from intermittent sun-damaged skin. However, increased utilization of ancillary testing methods such as BRAFV600E immunohistochemistry and sequencing studies have made apparent a subgroup of benign-grade and intermediate-grade melanocytic neoplasms with Spitzoid morphology that harbor BRAFV600E mutations. We refer to these cases as BRAF mutated and morphologically Spitzoid (BAMS) nevi and tumors. Two experienced dermatopathologists reviewed a series of 36 BAMS nevi/tumors. Cases in which a diagnosis of melanoma was favored were excluded. The histomorphologic, clinical, and molecular findings were assessed by immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing using validated gene panels. Characteristics of BAMS nevi/tumors were compared with a control set of Spitz tumors with previously reported fusion proteins. BAMS nevi/tumors had a decreased proportion of Kamino bodies (P=0.03) and a higher proportion of cytoplasmic pigmentation (P
- Published
- 2021